---
layout: default
title: Inositol
description: "Inositol 的老藥新用潛力分析。中等證據等級 L3，包含 10 個預測適應症。查看 AI 預測與臨床證據完整報告。"
parent: 中證據等級 (L3-L4)
nav_order: 87
evidence_level: L3
indication_count: 10
---

# Inositol

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
證據等級: <strong>L3</strong> | 預測適應症: <strong>10</strong> 個
</p>

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Inositol：從末梢血管循環障礙到 Familial Hypercholesterolemia

## 一句話總結

<p class="key-answer" data-question="Inositol 可以用於治療什麼新適應症？">
Inositol (肌醇) 及其衍生物原本用於末梢血管循環障礙治療。
TxGNN 模型預測它可能對 **Familial Hypercholesterolemia** (家族性高膽固醇血症) 有效，
目前有 **10 篇文獻** 支持這個方向，具有歷史臨床證據。
</p>


## 快速總覽

| 項目 | 內容 |
|------|------|
| 原適應症 | 末梢血管循環障礙、營養劑、趨脂劑 |
| 預測新適應症 | hepatoportal sclerosis、idiopathic copper-associated cirrhosis、early-onset familial noncirrhotic portal hypertension、hepatopulmonary syndrome、primitive portal vein thrombosis、hepatic porphyria、congestive heart failure、hyperlipoproteinemia、acute pulmonary heart disease、glycogen storage disease due to hepatic glycogen synthase deficiency |
| TxGNN 預測分數 | 99.47% |
| 證據等級 | L3 |
| 台灣上市 | 已上市(部分已註銷) |
| 許可證數 | 404 張(多數已註銷) |
| 建議決策 | Consider |






## 預測適應症詳細分析

<details class="indication-section" open>
<summary>
<span class="indication-name">1. hepatoportal sclerosis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.98%</span> <span class="primary-badge">主要分析</span>
</summary>
<div class="indication-content">

<h3>為什麼這個預測合理？</h3>

<p>Inositol Niacinate (菸鹼酸肌醇酯) 是 Inositol 與菸鹼酸的結合物，具有以下降血脂機轉：</p>

<ol>
<li><strong>菸鹼酸釋放</strong>：Inositol Niacinate 在體內水解釋放菸鹼酸，可抑制脂肪組織脂解，減少肝臟 VLDL 合成</li>
<li><strong>降低 LDL-C 和三酸甘油酯</strong>：多項歷史研究顯示可降低血清膽固醇 20% 和三酸甘油酯 40%</li>
<li><strong>相對良好的耐受性</strong>：比純菸鹼酸的潮紅副作用較輕</li>

</ol>
<p>此預測在機轉上合理，因為菸鹼酸類藥物歷史上曾用於高血脂症治療。</p>

<h3>臨床試驗</h3>

<p>目前無針對此特定適應症的臨床試驗登記。</p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. idiopathic copper-associated cirrhosis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.98%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. early-onset familial noncirrhotic portal hypertension</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.98%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. hepatopulmonary syndrome</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.98%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. primitive portal vein thrombosis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.98%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. hepatic porphyria</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.98%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. congestive heart failure</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.44%</span>
</summary>
<div class="indication-content">

<h3>相關文獻（20 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30971818/" target="_blank">30971818</a></td><td>2019</td><td>Article</td><td>Nature</td><td>Nitrosative stress drives heart failure with preserved ejection fraction.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/40583767/" target="_blank">40583767</a></td><td>2025</td><td>Article</td><td>Circulation</td><td>Mitochondrial Tumor Suppressor 1A Attenuates Myocardial Infarction Injury by Mai...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/40489543/" target="_blank">40489543</a></td><td>2025</td><td>Article</td><td>Circulation</td><td>FMO2 Prevents Pathological Cardiac Hypertrophy by Maintaining the ER-Mitochondri...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37874641/" target="_blank">37874641</a></td><td>2023</td><td>Article</td><td>The Journal of clinical invest</td><td>Impaired T cell IRE1α/XBP1 signaling directs inflammation in experimental heart ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31516082/" target="_blank">31516082</a></td><td>2019</td><td>Article</td><td>Cell cycle (Georgetown, Tex.)</td><td>The expanding phenotypes of cohesinopathies: one ring to rule them all!</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39121579/" target="_blank">39121579</a></td><td>2024</td><td>Article</td><td>EBioMedicine</td><td>Plasma myo-inositol elevation in heart failure: clinical implications and progno...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/22834797/" target="_blank">22834797</a></td><td>2012</td><td>Article</td><td>Current medicinal chemistry</td><td>Chromogranins and inositol 1,4,5-trisphosphate-dependent Ca(2+)-signaling in car...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37423398/" target="_blank">37423398</a></td><td>2023</td><td>Article</td><td>Gene</td><td>Expression profiles and potential functions of microRNAs in heart failure patien...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/20531218/" target="_blank">20531218</a></td><td>2010</td><td>Article</td><td>Journal of cardiovascular phar</td><td>Cardiac hypertrophy and heart failure development through Gq and CaM kinase II s...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38836349/" target="_blank">38836349</a></td><td>2024</td><td>Article</td><td>Circulation</td><td>IRE1α Mediates the Hypertrophic Growth of Cardiomyocytes Through Facilitating th...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38581016/" target="_blank">38581016</a></td><td>2024</td><td>Article</td><td>Microbiome</td><td>Longitudinal multi-omics analysis uncovers the altered landscape of gut microbio...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38952183/" target="_blank">38952183</a></td><td>2024</td><td>Article</td><td>British journal of pharmacolog</td><td>Myo-inositol trispyrophosphate prevents right ventricular failure and improves s...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38254653/" target="_blank">38254653</a></td><td>2023</td><td>Article</td><td>Biomolecules</td><td>Increased Risk for Atrial Alternans in Rabbit Heart Failure: The Role of Ca2+/Ca...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/19232951/" target="_blank">19232951</a></td><td>2008</td><td>Article</td><td>Trends in cardiovascular medic</td><td>Cardioprotective signaling by endothelin.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/11401928/" target="_blank">11401928</a></td><td>2001</td><td>Article</td><td>Circulation</td><td>Correlation of cerebral metabolites with clinical outcome among patients with se...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/11273716/" target="_blank">11273716</a></td><td>2001</td><td>Article</td><td>Journal of molecular and cellu</td><td>Ryanodine receptors/calcium release channels in heart failure and sudden cardiac...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28303572/" target="_blank">28303572</a></td><td>2017</td><td>Article</td><td>The Journal of physiology</td><td>Intracellular calcium release channels: an update.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30731143/" target="_blank">30731143</a></td><td>2019</td><td>Article</td><td>Life sciences</td><td>Metabolomic analysis of serum and myocardium in compensated heart failure after ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/33063821/" target="_blank">33063821</a></td><td>2020</td><td>Article</td><td>Clinical science (London, Engl</td><td>Cardiovascular toxicity of PI3Kα inhibitors.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/29625179/" target="_blank">29625179</a></td><td>2018</td><td>Article</td><td>Biochimica et biophysica acta.</td><td>Proteostasis in epicardial versus subcutaneous adipose tissue in heart failure s...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. hyperlipoproteinemia</span>
<span class="evidence-badge evidence-L3">L3</span>
<span class="prediction-score">99.40%</span>
</summary>
<div class="indication-content">

<h3>臨床試驗（1 項）</h3>

<table>
<thead>
<tr><th>試驗編號</th><th>階段</th><th>狀態</th><th>人數</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04887675" target="_blank">NCT04887675</a></td><td>NA</td><td>UNKNOWN</td><td>120</td><td>A Single Centre, Prospective, Two-armed Magnetic Resonance Spectroscopy Study to...</td></tr>
</tbody>
</table>

<h3>相關文獻（10 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/6683558/" target="_blank">6683558</a></td><td>1983</td><td>Article</td><td>Arzneimittel-Forschung</td><td>[Effect of a clofibrate-inositol nicotinate combination on lipids and lipoprotei...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37827478/" target="_blank">37827478</a></td><td>2023</td><td>Article</td><td>Chemistry and physics of lipid</td><td>Lipidomic analysis identified potential predictive biomarkers of statin response...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/196436/" target="_blank">196436</a></td><td>1976</td><td>Article</td><td>Verhandlungen der Deutschen Ge</td><td>[The problem of type changes in hyperlipoproteinemia (type IIb, IV, V) under clo...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/1253701/" target="_blank">1253701</a></td><td>1976</td><td>Article</td><td>Deutsche medizinische Wochensc</td><td>[Treatment of hyperlipoproteinaemia types IIa, IIb, IV and V with a combination ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/203832/" target="_blank">203832</a></td><td>1978</td><td>Article</td><td>Medizinische Klinik</td><td>[Combination or monotherapy of hyperlipoproteinemia typus IIb, IV, V with clofib...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/7458676/" target="_blank">7458676</a></td><td>1980</td><td>Article</td><td>Artery</td><td>Changes in lipids and lipoproteins in patients with hyperlipidemia type IIb, IV ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/7890011/" target="_blank">7890011</a></td><td>1994</td><td>Article</td><td>European journal of clinical i</td><td>Platelet transmembrane signalling responses to collagen in familial hypercholest...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/7259531/" target="_blank">7259531</a></td><td>1980</td><td>Article</td><td>Artery</td><td>Lipids and lipoproteins in hyperlipidemia type IIa during treatment with differe...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/583231/" target="_blank">583231</a></td><td>1979</td><td>Article</td><td>Arzneimittel-Forschung</td><td>[Treatment of various types of hyperlipoproteinaemia with a combination of Mg-ch...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/4603893/" target="_blank">4603893</a></td><td>1974</td><td>Article</td><td>Therapie der Gegenwart</td><td>[The management of hyperlipoproteinemia with Liproreduct].</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. acute pulmonary heart disease</span>
<span class="evidence-badge evidence-L3">L3</span>
<span class="prediction-score">99.34%</span>
</summary>
<div class="indication-content">

<h3>臨床試驗（1 項）</h3>

<table>
<thead>
<tr><th>試驗編號</th><th>階段</th><th>狀態</th><th>人數</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT07278206" target="_blank">NCT07278206</a></td><td>NA</td><td>RECRUITING</td><td>66</td><td>Mitigating Cognitive Problems and Fatigue With Brain Stimulation in Long COVID</td></tr>
</tbody>
</table>

<h3>相關文獻（5 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/41253746/" target="_blank">41253746</a></td><td>2025</td><td>Article</td><td>Signal transduction and target</td><td>Therapeutic targeting of endothelial calcium signaling accelerates the resolutio...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38860845/" target="_blank">38860845</a></td><td>2024</td><td>Article</td><td>American journal of physiology</td><td>Activation of alveolar epithelial ER stress by β-coronavirus infection disrupts ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/20870804/" target="_blank">20870804</a></td><td>2010</td><td>Article</td><td>American journal of physiology</td><td>Urotensin II receptor antagonist attenuates monocrotaline-induced cardiac hypert...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/2099571/" target="_blank">2099571</a></td><td>1990</td><td>Article</td><td>Respiration; international rev</td><td>PAF-dependent phosphatidylinositol turnover in platelets: differences between as...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/24888919/" target="_blank">24888919</a></td><td>2014</td><td>Article</td><td>The journal of obstetrics and </td><td>Hypoxia-induced cytosolic calcium influx is mediated primarily by the reverse mo...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. glycogen storage disease due to hepatic glycogen synthase deficiency</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.26%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>


## 台灣上市資訊

| 許可證號 | 品名 | 劑型 | 核准適應症 | 狀態 |
|---------|------|------|-----------|------|
| 內衛藥製字第000394號 | "強生"血管淨錠 | 錠劑 | 末梢血管循環障礙 | 有效 |
| 多張歷史許可證 | 各品牌 Inositol Niacinate 製劑 | 錠劑/粉末 | 末梢血管障礙、趨脂劑 | 多數已註銷 |

## 安全性考量

- **藥物交互作用**：目前 DDI 資料庫中未發現顯著交互作用

- **已知副作用**：
  - 潮紅反應（比純菸鹼酸輕微）
  - 胃腸不適
  - 肝功能異常（長期高劑量使用）

## 結論與下一步

**決策：Consider**

**理由：**
Inositol Niacinate 用於高血脂症有歷史臨床證據支持，尤其是 1970-1980 年代的研究。然而，現代降血脂治療已有更有效的選擇（如 Statin 類藥物），此藥物的臨床定位需重新評估。

**若要推進需要：**
- 進行現代標準的隨機對照試驗，與現行標準治療比較
- 評估在 Statin 不耐受患者中的替代治療角色
- 確認現代製劑品質與藥動學特性
- 考慮與現代降血脂藥物的合併療法潛力


---

## 相關藥物報告

- [Human Immunoglobulin G]({{ "/drugs/human_immunoglobulin_g/" | relative_url }}) - 證據等級 L3
- [Durvalumab]({{ "/drugs/durvalumab/" | relative_url }}) - 證據等級 L3
- [Vinorelbine]({{ "/drugs/vinorelbine/" | relative_url }}) - 證據等級 L3
- [Interferon Beta-1B]({{ "/drugs/interferon_beta-1b/" | relative_url }}) - 證據等級 L3
- [Lornoxicam]({{ "/drugs/lornoxicam/" | relative_url }}) - 證據等級 L3

---

{% include ai-analysis.html %}

{% include social-share.html %}

## 引用本報告

如需引用本報告，請使用以下格式：

**APA 格式：**
```
TwTxGNN. (2026). Inositol老藥新用驗證報告. https://twtxgnn.yao.care/drugs/inositol/
```

**BibTeX 格式：**
```bibtex
@misc{twtxgnn_inositol,
  title = {Inositol老藥新用驗證報告},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/inositol/}
}
```

---

<div class="disclaimer">
<strong>免責聲明</strong><br>
本報告僅供學術研究參考，<strong>不構成醫療建議</strong>。藥物使用請遵循醫師指示，切勿自行調整用藥。任何老藥新用決策需經過完整的臨床驗證與法規審查。
<br><br>
<small>最後審核：2026-02-20 | 審核者：TwTxGNN Research Team</small>
</div>

{% include giscus.html %}
